CRISPR-GEMM Pooled Mutagenic Screening Identifies KMT2D as a Major Modulator of Immune Checkpoint Blockade.
Wang G, Chow RD, Zhu L, Bai Z, Ye L, Zhang F, Renauer PA, Dong MB, Dai X, Zhang X, Du Y, Cheng Y, Niu L, Chu Z, Kim K, Liao C, Clark P, Errami Y, Chen S.
Wang G, et al.
Cancer Discov. 2020 Dec;10(12):1912-1933. doi: 10.1158/2159-8290.CD-19-1448. Epub 2020 Sep 4.
Cancer Discov. 2020.
PMID: 32887696
Free PMC article.